Related Experiment Video
Updated: Jul 16, 2026
07:05
Behavioral Disturbances: An Innovative Approach to Monitor the Modulatory Effects of a Nutraceutical Diet
Published on: January 3, 2017
Phenobarbital-responsive episodic dyscontrol (rage) in dogs
N H Dodman1, K A Miczek, K Knowles
1Department of Surgery, Tufts University School of Veterinary Medicine, North Grafton, MA 01536.
Journal of the American Veterinary Medical Association
|November 15, 1992
Summary
Episodic dyscontrol, a rage disorder in dogs, was diagnosed using clinical signs and EEG. Phenobarbital treatment effectively managed aggressive incidents and improved behavior in affected canines.
Area of Science:
- Veterinary Neurology
- Canine Behavior Medicine
- Epilepsy Research
Background:
- Episodic dyscontrol, characterized by sudden aggressive outbursts, presents a diagnostic challenge in veterinary medicine.
- Understanding the neurological underpinnings of such behavioral changes is crucial for effective treatment.
Observation:
- Three dogs presented with clinical histories indicative of episodic dyscontrol (rage).
- Key features included mood changes preceding aggression, explosive outbursts, and post-incident lethargy.
- Electroencephalographic (EEG) recordings revealed abnormal spike activity, particularly in temporal regions.
Findings:
- Diagnosis was confirmed through clinical evaluation, EEG abnormalities, and positive response to phenobarbital.
- Phenobarbital, an anticonvulsant medication, demonstrated efficacy in controlling the aggressive episodes.
- Abnormal temporal spike activity on EEG correlated with the episodic dyscontrol syndrome.
Implications:
- This study highlights phenobarbital as a viable treatment option for episodic dyscontrol in dogs.
- Findings suggest a potential link between temporal lobe abnormalities and rage-like behavior in canines.
- Further research into the neurobiology of episodic dyscontrol may improve diagnostic and therapeutic strategies.
Related Concept Videos
01:14CNS Depressants: Barbiturates and Benzodiazepines
CNS depressants include drugs from the category of barbiturates and benzodiazepines. They are valuable medications for managing anxiety disorders and insomnia. Barbiturates, once used to induce and maintain sleep, have been replaced mainly by benzodiazepines due to barbiturate's toxicity, tolerance, and overdose risks. They interact with GABAA receptors, leading to sedation at low doses and potentially coma and death at higher doses. Phenobarbital, a long-acting barbiturate, possesses...
01:24Mania and Antimanic Drugs: Overview
Mania, a psychological condition characterized by elevated mood, increased energy, and reduced sleep need, is part of the bipolar disorder cycle. The exact cause of mania isn't entirely known, but it is thought to be a combination of genetic, environmental, and neurological factors. Bipolar disorder involves alternating manic and depressive episodes. Mood stabilizers like lithium, antipsychotics, and anticonvulsants help manage these episodes. Lithium carbonate is particularly effective as a...
01:20Sedatives and Hypnotics Drugs: Barbiturates
Sedatives and hypnotics encompass a drug class that acts on the central nervous system (CNS) to alleviate anxiety, promote relaxation and induce sleep.These drugs function by amplifying the actions of the neurotransmitter γ-aminobutyric acid (GABA), resulting in reduced neuronal activity. Barbiturates, a subset of sedatives and hypnotics first synthesized in the late 1800s, are categorized into ultra-short, short, intermediate, and long-acting groups based on their duration of effect. A key...
01:18Antiepileptic Drugs: GABAergic Pathway Potentiators
γ-aminobutyric acid or GABA, plays a pivotal role as an inhibitory neurotransmitter in the brain. GABA pathway potentiators, also known as GABAergic drugs, are a class of pharmaceutical agents designed to enhance the functioning of the GABAergic system. These medications primarily treat epilepsy, a neurological disorder characterized by recurrent seizures.
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for their...
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for their...
01:20Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein
Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
01:15REM Sleep Behavior Disorder
REM Sleep Behavior Disorder (RBD) is a sleep disorder characterized by the absence of muscle paralysis that normally occurs during the REM phase of sleep. This absence allows individuals to physically act out their dreams, which are often vivid and disturbing. Common behaviors exhibited during episodes include kicking, punching, and yelling. These actions can be dangerous, potentially leading to injuries for the person with RBD or their bed partner.
RBD is significantly associated with...
RBD is significantly associated with...